Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limi...